Artios deal fourth for synthetic lethality in 2020: Data Byte

Artios and Merck KGaA’s deal marks the fourth time a large company partnered with a synthetic lethality-focused biotech this year, signaling continuing momentum for the tumor-targeting strategy.

The principle of synthetic lethality is that while cancer cells can tolerate or even benefit from loss of function in one gene, simultaneous inhibition of a second gene causes overwhelming genetic damage that triggers tumor-specific cell death...